124 related articles for article (PubMed ID: 20219372)
21. A Selective Bombesin Receptor Subtype 3 Agonist Promotes Weight Loss in Male Diet-Induced-Obese Rats With Circadian Rhythm Change.
Nio Y; Hotta N; Maruyama M; Hamagami K; Nagi T; Funata M; Sakamoto J; Nakakariya M; Amano N; Okawa T; Arikawa Y; Sasaki S; Okuda S; Kasai S; Habata Y; Nagisa Y
Endocrinology; 2017 May; 158(5):1298-1313. PubMed ID: 28324017
[TBL] [Abstract][Full Text] [Related]
22. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach.
Matsufuji T; Shimada K; Kobayashi S; Ichikawa M; Kawamura A; Fujimoto T; Arita T; Hara T; Konishi M; Abe-Ohya R; Izumi M; Sogawa Y; Nagai Y; Yoshida K; Abe Y; Kimura T; Takahashi H
Bioorg Med Chem; 2015 Jan; 23(1):89-104. PubMed ID: 25497965
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2).
Darker JG; Brough SJ; Heath J; Smart D
J Pept Sci; 2001 Nov; 7(11):598-605. PubMed ID: 11763364
[TBL] [Abstract][Full Text] [Related]
25. Pharmacology and intracellular signaling mechanisms of the native human orphan receptor BRS-3 in lung cancer cells.
Ryan RR; Weber HC; Mantey SA; Hou W; Hilburger ME; Pradhan TK; Coy DH; Jensen RT
J Pharmacol Exp Ther; 1998 Oct; 287(1):366-80. PubMed ID: 9765358
[TBL] [Abstract][Full Text] [Related]
26. The design of a new potent and selective ligand for the orphan bombesin receptor subtype 3 (BRS3).
Boyle RG; Humphries J; Mitchell T; Showell GA; Apaya R; Iijima H; Shimada H; Arai T; Ueno H; Usui Y; Sakaki T; Wada E; Wada K
J Pept Sci; 2005 Mar; 11(3):136-41. PubMed ID: 15635635
[TBL] [Abstract][Full Text] [Related]
27. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
Zhu C; Hansen AR; Bateman T; Chen Z; Holt TG; Hubert JA; Karanam BV; Lee SJ; Pan J; Qian S; Reddy VB; Reitman ML; Strack AM; Tong V; Weingarth DT; Wolff MS; MacNeil DJ; Weber AE; Duffy JL; Edmondson SD
Bioorg Med Chem Lett; 2008 Aug; 18(15):4393-6. PubMed ID: 18614364
[TBL] [Abstract][Full Text] [Related]
28. Design of selective peptidomimetic agonists for the human orphan receptor BRS-3.
Weber D; Berger C; Eickelmann P; Antel J; Kessler H
J Med Chem; 2003 May; 46(10):1918-30. PubMed ID: 12723954
[TBL] [Abstract][Full Text] [Related]
29. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Dosa PI; Covel JA; Ren A; Webb RR; Beeley NR; Martin M; Morgan M; Espitia S; Saldana HR; Bjenning C; Whelan KT; Grottick AJ; Menzaghi F; Thomsen WJ
J Med Chem; 2008 Jan; 51(2):305-13. PubMed ID: 18095642
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.
Hadden M; Deering DM; Henderson AJ; Surman MD; Luche M; Khmelnitsky Y; Vickers S; Viggers J; Cheetham S; Guzzo PR
Bioorg Med Chem Lett; 2010 Dec; 20(23):7020-3. PubMed ID: 20951036
[TBL] [Abstract][Full Text] [Related]
31. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
[TBL] [Abstract][Full Text] [Related]
32. Pyridinesulfonylureas and pyridinesulfonamides as selective bombesin receptor subtype-3 (BRS-3) agonists.
Lo MM; Chobanian HR; Palyha O; Kan Y; Kelly TM; Guan XM; Reitman ML; Dragovic J; Lyons KA; Nargund RP; Lin LS
Bioorg Med Chem Lett; 2011 Apr; 21(7):2040-3. PubMed ID: 21354793
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
[TBL] [Abstract][Full Text] [Related]
34. Discovery and SAR of new benzazepines as potent and selective 5-HT(2C) receptor agonists for the treatment of obesity.
Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Thomsen WJ; Saldana HR; Whelan KT; Menzaghi F; Webb RR; Beeley NR
Bioorg Med Chem Lett; 2005 Mar; 15(5):1467-70. PubMed ID: 15713408
[TBL] [Abstract][Full Text] [Related]
35. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
36. Spiroindane based amides as potent and selective MC4R agonists for the treatment of obesity.
He S; Ye Z; Dobbelaar PH; Sebhat IK; Guo L; Liu J; Jian T; Lai Y; Franklin CL; Bakshi RK; Dellureficio JP; Hong Q; Weinberg DH; Macneil T; Tang R; Strack AM; Tamvakopoulos C; Peng Q; Miller RR; Stearns RA; Chen HY; Chen AS; Fong TM; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4399-405. PubMed ID: 20598882
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.
Sancho V; Moody TW; Mantey SA; Di Florio A; Uehara H; Coy DH; Jensen RT
Peptides; 2010 Aug; 31(8):1569-78. PubMed ID: 20438784
[TBL] [Abstract][Full Text] [Related]
38. Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
Souers AJ; Gao J; Brune M; Bush E; Wodka D; Vasudevan A; Judd AS; Mulhern M; Brodjian S; Dayton B; Shapiro R; Hernandez LE; Marsh KC; Sham HL; Collins CA; Kym PR
J Med Chem; 2005 Mar; 48(5):1318-21. PubMed ID: 15743174
[TBL] [Abstract][Full Text] [Related]
39. 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
Ohmori J; Shimizu-Sasamata M; Okada M; Sakamoto S
J Med Chem; 1997 Jun; 40(13):2053-63. PubMed ID: 9207947
[TBL] [Abstract][Full Text] [Related]
40. Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.
Smith RA; Fathi Z; Achebe F; Akuche C; Brown SE; Choi S; Fan J; Jenkins S; Kluender HC; Konkar A; Lavoie R; Mays R; Natoli J; O'Connor SJ; Ortiz AA; Su N; Taing C; Tomlinson S; Tritto T; Wang G; Wirtz SN; Wong W; Yang XF; Ying S; Zhang Z
Bioorg Med Chem Lett; 2007 May; 17(10):2706-11. PubMed ID: 17383180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
